#USA #Denver #EmVenio Clinical Research #PCM Trials #Clinical Trial Service

EmVenio Clinical Research: Elevating Clinical Trials Access

On August 25, 2025, a significant transformation occurred in the world of clinical trials. PCM Trials, along with its subsidiaries EmVenio Research and Clinical Trial Service, have unified under the brand name EmVenio Clinical Research. This strategic consolidation merges the distinct strengths of these entities, creating a more flexible and expansive service for sponsors and contract research organizations (CROs).

Greg Austin, President of PCM Trials and now leading EmVenio Clinical Research, emphasized that this merger establishes a new industry benchmark for reach, access, and accuracy in community-based clinical research. With this rebranding, the goal is to enhance accessibility for potential study participants, allowing individuals to enroll and remain in trials more easily than ever before. This ambition extends not just within North America, but also throughout Europe and beyond.

Unifying Strengths for Greater Impact

EmVenio, now operating in over 80 countries, deploys mobile teams and local research sites to meet participants in their communities—right where they live and work. The brand aims to be more than a name; it's a commitment to overcoming barriers that have historically hindered participation in clinical research.

A central part of this initiative is the launch of the Patient Navigator™, a personalized support service designed to alleviate logistical and financial challenges associated with clinical trial participation. This service is especially crucial in therapeutic areas where involvement can be notably burdensome, such as in pediatric studies and for patients with rare diseases. The Patient Navigator offers flexible assistance—coordinating travel arrangements, accommodation, and reimbursement options—creating pathways for patients to engage in studies without added stress.

A Proven Track Record and Innovative Approach

Founded in 2008, PCM Trials has grown to be a leading provider of decentralized clinical trials, with registered nurses conducting studies in the comfort of patients' homes. Many of PCM's innovations are now viewed as standards in clinical research. Following its acquisition of the Clinical Trial Service in 2024 and EmVenio Research shortly after, a powerful alliance was formed, focusing on expanding global access to clinical studies.

Under the EmVenio brand, clinical research organizations and sponsors now benefit from decades of experience along with a robust operational reach, recruiting over 75% minority patients and achieving over 92% retention rates among study participants. Austin stated, “The brand name EmVenio encapsulates our vision for the future of research. It merges the idea of 'empowerment' with the Latin word 'venio,' meaning 'to reach,' which reflects our mission to connect with patients in ways that traditional models cannot.”

Community-Centric Research to Enhance Health Outcomes

EmVenio Clinical Research operates from headquarters in the U.S. and Europe, backed by a force of approximately 5,000 professionals dedicated to supporting clinical studies in over 80 countries. Their community-centered approach brings studies directly to patients—whether in their homes, local centers, or familiar gathering places—enabling diverse populations that have been overlooked by conventional models to participate actively.

Their efforts to bridge the gap between science and the communities it serves reflect a deeper understanding that real progress in health can only occur when research mirrors the realities of everyday lives. This profound level of empathy and expertise promises to enrich the landscape of clinical trials, ensuring a comprehensive portrayal of human health.

As EmVenio Clinical Research moves forward, they remain committed to transforming the landscape of clinical trials access and participant support, ensuring that the future of medical research is inclusive and grounded in real-world experiences. For more information, visit EmVenio.